Board of Directors
All the members of the Board of Directors were elected at the Annual General Meeting for a term of one year.
Born in 1957
Member of the board of directors since the year 2005
Master’s degree in Business Administration from the University of Aarhus in Denmark
Nissens A/S (chairman)
KIRKBI A/S (deputy chairman)
The Thomas B. Thrige Foundation (chairman)
ABOUT YOU Holding GmbH (deputy chairman)
Additional duties related to William Demant Invest A/S:
Demant A/S, deputy chairman
Jeudan A/S, chairman
Vision RT Ltd. (chairman)
Founders A/S (chairman)
Boston Holding A/S (board member)
Össur hf., chairman
Mr. Jacobsen has broad management experience both as CEO and as chairman in major international companies, he is currently the CEO of William Demant Invest A/S. Previous positions include President & CEO of Demant A/S (formerly William Demant Holding A/S), President of Orion A/S and Vice President overseeing corporate affairs for both Atlas Danmark A/S and Thrige-Titan A/S.
Mr. Jacobsen has no interest links with the Company’s main clients or competitors. Mr. Jacobsen is the CEO of William Demant Invest A/S, the Company’s largest shareholder, and he is a dependent member of the Board.
Born in 1968
Member of the board of directors since the year 2009
Master’s degree in Business Administration from the Copenhagen Business School in Denmark
Epos A/S (chairman)
Revenio Group Oyj (board member)
Interacoustics A/S (president)
Mr. Nielsen has spent his entire career with Demant A/S in various and expanding roles throughout the world. After working as an interim General Manager of Oticon Australia Pty Ltd. Mr. Nielsen assumed, in 1996, his current position as President of Diagnostics and Communications in Demant, which has operations worldwide.
Mr. Nielsen has no interest links with the Company’s main clients or competitors. Mr. Nielsen is employed by Demant A/S, whose largest shareholder is William Demant Invest A/S (the Company’s largest shareholder), and he is a dependent member of the Board.
Born in 1957
Member of the board of directors since the year 2021
Dr. Esquenazi received his medical degree in Medicine and Surgery from Universidad Nacional Autonoma de Mexico. He completed his residency in PM&R at Temple University and a fellowship in gait analysis and prosthetic research at MossRehab. His research focuses on gait analysis, limb prosthetics, orthotics, spasticity management and robotics and technology in rehabilitation.
Past president of the American Academy of PM&R and member of the board of AMRPA and Einstein Healthcare Network.
Alberto Esquenazi, MD, serves as the John Otto Haas Chair of the Department of Physical Medicine and Rehabilitation at MossRehab, in Philadelphia and is the Chief Medical Officer as well as Director of the Gait and Motion Analysis Laboratory and Clinical Director of the Regional Amputee Center. He is Professor of PM&R at Jefferson School of Medicine. Dr. Esquenazi has published widely and is a member of national and international professional, educational, and research societies.
Dr. Esquenazi has no interest links with the Company‘s main clients, competitors or major shareholders. Dr. Esquenazi is an independent member of the Board.
Born in 1965
Member of the board of directors since the year 2008
Doctorate in Industrial Relations from the London School of Economics
Icelandair (board member)
Origo (board member)
UNICEF Iceland (board member)
Mynto (board member)
Dr. Grönfeldt is the senior advisor to the Dean at the Massachusetts Institute of Technology SA+P, a founding member of MIT’s newest innovation accelerator DesignX, and a co-founder of the MET fund, a Cambridge based seed investment fund. Previous positions include Chief Organizational Development Officer of Alvogen, President of Reykjavik University, deputy to the CEO of Actavis Group, Assistant Professor of Economics and Business Administration at the University of Iceland.
Dr. Grönfeldt has no interest links with the Company’s main clients, competitors, or major shareholders. Dr. Grönfeldt is a dependent member of the Board due to tenure.
Born in 1951
Member of the board of directors since the year 2013
Master’s degree (Pharm.) from Copenhagen University
Brunnur Investment Fund (chairman)
Coripharma Holding ehf (vice chairman)
Orf Genetics hf. (board member)
Florealis ehf. (chairman)
Vistor hf. (board member)
Saga Medica ehf. (board member)
Pretium ehf. (chairman)
Previous positions include President & EVP Strategic Projects of Actavis Plc in Iceland, a global integrated specialty pharmaceutical company; Deputy CEO and EVP Third Party Sales at Actavis Group hf.; Deputy CEO, Head of R&D, Assistant Managing Director, Development Manager, Regulatory Manager and Marketing Manager at Delta hf.; and Medical Representative at Pharmaco hf. She was the President of the European Generic Medicines Association from 2011-2013.
Ms. Eggertsdóttir has no interest links with the Company’s main clients or competitors. Ms. Eggertsdóttir is an independent member of the Board.
The Board of Directors is the supreme authority in Össur’s affairs between Shareholders’ Meetings. The Board has various roles and responsibilities, including establish goals for the Company and formulate the policy and strategy to achieve those goals, hire a CEO to manage the Company’s daily operations, supervise the Company’s activities and ensure that the Company’s organization and operations are in good and proper order, ensure adequate surveillance of the accounting and financial management of the Company, and evaluate the Company’s capital structure as well as the performance of the Board and the CEO. The Board’s roles and responsibilities are further described in the Board’s rules of procedure, which are available here.